Journal article

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

Victoria Atkinson, Shahneen Sandhu, Geke Hospers, Georgina Long, Massimo Aglietta, Pier F Ferrucci, Skaiste Tulyte, Gian Carlo Antonini Cappellini, Virtudes Soriano, Sayed Ali, Alexandr Poprach, Alvydas Cesas, Delvys Rodriguez-Abreu, Mike Lau, Egbert de Jong, Philippe Legenne, Dara Stein, Brianna King, Johannes van Thienen

Melanoma Research | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020


In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-agent BRAF inhibitors (BRAFi) in patients with BRAF V600-mutant unresectable or metastatic melanoma. We investigated dabrafenib plus trametinib therapy in a compassionate-use setting [Named Patient Program (NPP); DESCRIBE II]. A retrospective chart review of patients with BRAF V600-mutated unresectable stage III/IV melanoma receiving dabrafenib plus trametinib as compassionate use was conducted. Treatment patterns and duration, clinical outcomes, and tolerability were evaluated. Of 271 patients, 92.6% had stage IV melanoma, including 36.5% with brain metastases. Overall, 162 patients (59.8%) we..

View full abstract


Funding Acknowledgements

We thank the patients and their families for their participation in the study. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. We thank Staci Heise, PhD, and Amanda L. Kauffman, PhD, of ArticulateScience LLC, for medical editorial assistance with this manuscript. This work was supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of March 2, 2015.